Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association
Coherus BioSciences, Inc. – Remaining general survival evaluation of the JUPITER-02 trial reveals first-line therapy with LOQTORZI plus chemotherapy considerably prolongs survival in sufferers with recurrent or metastatic NPC no…